AAD
  • Registration
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Program
  • Media Gallery
Topics
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Program
  • Media Gallery
Resources
  • Registration
Facebook iconInstagram iconTwitter icon
Feb 14, 2022

Novel uses for JAK inhibitors part of comprehensive What’s New session

Pathogenesis-directed drug therapy is only beginning to find a role in dermatology.


Seemal R. Desai, MD, FAAD.
Seemal R. Desai, MD, FAAD.

S062 – What’s New in Dermatology

Tuesday, March 29 | 8 a.m. – 10 a.m.

Ballroom West

Hope is on the horizon for patients seeking relief from the symptoms related to vitiligo, atopic dermatitis, alopecia, and psoriasis, and that hope may just come in the form of a pathogenesis-directed drug therapy long used to treat rheumatoid arthritis — Janus kinase (JAK) inhibitors.

The 2022 AAD Annual Meeting will shed light on that discovery and more during the session, S062 – What’s New in Dermatology. JAK inhibitors are only beginning to find a role in dermatology and will provide new treatment opportunities for dermatologists and patients alike, according to session panelist, Seemal R. Desai, MD, FAAD, founder and medical director of Innovative Dermatology PA in Plano, Texas.

“The JAK inhibitor baricitinib will be the first FDA-approved therapy for alopecia areata ever,” Dr. Desai said of the disease that takes an emotional toll on patients. “We don’t have an exact date yet, but the data look good.”

In the fall of 2021, the FDA approved the use of JAK inhibitors in topical form for atopic dermatitis, he said. Soon, the FDA is expected to approve the use of JAK inhibitors to treat vitiligo and issue its approval for the JAK inhibitor deucravactinib to treat psoriasis, Dr. Desai said.

In addition to the closer look at the use of JAK inhibitors in dermatology, the Tuesday, March 29 session is wide-ranging and will explore an array of updates by noted speakers:

  • What's New in Psoriasis?: Bruce Elliot Strober, MD, PhD, FAAD
  • What's New in Surgical Dermatology?: Brett M. Coldiron, MD, FAAD
  • What's New in the Diagnosis and Treatment of Cutaneous Malignancy?: Darrell S. Rigel, MD, FAAD
  • What's New in Cosmetic Dermatology?: Mark S. Nestor, MD, PhD, FAAD
  • What's New in Pediatric Dermatology?: Lawrence F Eichenfield, MD, FAAD
  • What's New in Mild to Moderate Psoriasis?: Linda F. Stein Gold, MD, FAAD
  • What's New in Systemic Dermatologic Therapy?: Seemal R. Desai, MD, FAAD

There will also be a Q&A with session director, Mark Lebwohl, MD, FAAD. 

Visit AAD DermWorld Meeting News Central for more articles.

Interesting Stories
Advancing Therapeutic Conversations
Presented by AbbVie
Advancing Therapeutic Conversations
Prurigo Nodularis and Atopic Dermatitis:
Presented by Sanofi and Regeneron Pharmaceuticals, Inc.
Prurigo Nodularis and Atopic Dermatitis:
What makes a biosimilar and an Interchangeable biosimilar different?
Presented by Boehringer Ingelheim
What makes a biosimilar and an Interchangeable biosimilar different?
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
Presented by Neutrogena
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
Join Us to Learn More About SOTYKTU<sup>TM</sup> (deucravacitinib):
Presented by Bristol Myers Squibb
Join Us to Learn More About SOTYKTUTM (deucravacitinib):
Janssen-Sponsored Symposium
Presented by Janssen Biotech, Inc.
Janssen-Sponsored Symposium
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
Presented by Pfizer Inc.
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
More in Daily Coverage
Session Director Raj Chovatiya, MD, PhD, FAAD
AAD 2023 Annual Meeting
When it looks and itches like atopic dermatitis. But isn’t.
Apr 07, 2023
Left to right: Kelly Tyler, MD, FAAD, and Howa Yeung, MD, FAAD
AAD 2023 Annual Meeting
Lifting the veil
Apr 07, 2023
Session director Trilokraj Tejasvi, MD, MBBS
AAD 2023 Annual Meeting
Decoding the benefits and burdens of technology in dermatology
Apr 07, 2023
Left to right: Rebecca I. Hartman, MD, MPH, FAAD, Abigail Baird Waldman, MD, FAAD, and Emily S. Ruiz, MD, FAAD.
AAD 2023 Annual Meeting
Surgery is not the only option for skin cancers
Apr 07, 2023
Terrence A. Cronin Jr., MD, FAAD
AAD 2023 Annual Meeting
From 17 to 20,000: New president accepts challenge of Academy’s 85-year growth
Apr 07, 2023
Left to right: Maria Aleshin, MD, FAAD, and Silvina Pugliese, MD, FAAD
AAD 2023 Annual Meeting
Beyond the familiar
Apr 07, 2023
Safi Bahcall
AAD 2023 Annual Meeting
Nurture the unexpected
Mar 20, 2023
Richard L. Gallo, MD, PhD, FAAD
AAD 2023 Annual Meeting
New approach uses microbiome to treat skin disease
Mar 20, 2023
Camp Discovery 92
AAD 2023 Annual Meeting
Refer a patient to Camp Discovery!
Mar 20, 2023
Amy J. McMichael, MD, FAAD
AAD 2023 Annual Meeting
A question of belonging
Mar 20, 2023
David J. Margolis, MD, PhD, FAAD
AAD 2023 Annual Meeting
Dermatologists top the list in antibiotic prescriptions
Mar 20, 2023
22 698 Ia23 Web Card 3x2
AAD 2023 Annual Meeting
Mark your calendar for Innovation Academy 2023
Join the learning
Mar 20, 2023
AAD
Facebook iconInstagram iconTwitter icon
© Ascend Media All rights reserved. DermWorld Meeting News Central is a publication of the American Academy of Dermatology.